Table 5.

HRs of developing esophageal adenocarcinoma or its precursor lesions by polymorphisms of the IGF-I, IGBP-3, and IGF-IR genes among participants with Barrett's esophagus

n*Aneuploidy
Tetraploidy
Esophageal adenocarcinoma
No. cases/no. controlsHR (95% CI)No. cases/no. controlHR (95% CI)No. cases/no. controlsHR (95% CI)
IGF-I (CA)19 genotypes
    (CA)19/(CA)19136 (40%)13/111117/111116/1201
    (CA)19/(CA)non-19166 (48%)17/1280.9 (0.5-2.3)18/1250.9 (0.8-1.8)19/1471.0 (0.5-1.9)
    (CA)non-19/(CA)non-1941 (12%)5/341.1 (0.7-2.9)7/301.1 (0.4-2.6)3/380.5 (0.2-1.8)
    Ptrend0.91.00.4
IGFBP-3 −202 A/C genotypes
    AA65 (19%)3/5516/51110/551
    AC171 (50%)19/1352.4 (0.7-8.2)20/1371.2 (0.5-3.0)15/1560.6 (0.3-1.3)
    CC107 (31%)13/832.6 (0.7-9.1)16/781.6 (0.6-4.1)13/940.8 (0.4-1.9)
    Ptrend0.20.30.8
IGF-IR genotypes
    AGG repeats
        7,7111 (32%)13/89114/88114/971
        7,6174 (51%)15/1400.7 (0.3-1.5)19/1370.9 (0.4-1.8)20/1540.9 (0.4-9.8)
        6,654 (16%)6/410.9 (0.3-2.3)8/391.0 (0.4-2.5)3/510.4 (0.1-1.4)
        Others4 (1%)1/32.6 (0.3-19.7)1/22.8 (0.4-21.7)1/32.3 (0.3-17.5)
        Ptrend0.90.80.3
    2-bp deletion
        No deletion167 (49%)17/132117/135115/1521
        Heterozygote143 (42%)14/1160.9 (0.5-1.9)19/1071.3 (0.7-2.5)19/1241.5 (0.8-3.0)
        Homozygote33 (9%)4/251.4 (0.5-4.3)6/242.3 (0.9-5.9)4/291.5 (0.5-4.6)
        Ptrend0.40.10.3
  • * Total number of cases and controls may not add up to 343 due to exclusion criteria in each end-point analysis.